Aptus Pharma Ltd
Aptus Pharma Ltd (APPL) last reported results for the quarter ended Mar 2026, with sales of ₹32.2 crore and net profit of ₹2.87 crore. The stock last traded at ₹367, a market capitalisation of ₹629 crore, on a P/E of 136. Over the past 52 weeks the stock has ranged between ₹33.6 and ₹370. Figures are as of 6 Oct 2026 and are not real time.
Aptus Pharma Ltd share price and key metrics
- Current price
- ₹367
- Market cap
- ₹629 cr
- Stock P/E
- 136
- Book value
- ₹13.6
- ROE
- 30.5%
- ROCE
- 30.0%
- Dividend yield
- 0.00%
- 52w high / low
- 370/33.6
Metrics as of 6 Oct 2026. Not real time.
Track Aptus Pharma Ltd
Cruxal reads every Aptus Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Aptus Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 50%
- TTM
- 90%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 190%
- TTM
- 49%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 997%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 41%
- Last Year
- 30%
Aptus Pharma Ltd quarterly results
| ₹ crore | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 9.76 | 14.8 | 14.38 | 32.2 |
| Expenses | 7.78 | 11.93 | 11.45 | 27.7 |
| Operating profit | 1.98 | 2.87 | 2.93 | 4.5 |
| OPM % | 20.29% | 19.39% | 20.38% | 13.98% |
| Other income | 0 | 0.08 | 0.01 | 0.12 |
| Interest | 0.11 | 0.36 | 0.43 | 0.35 |
| Depreciation | 0.11 | 0.15 | 0.16 | 0.25 |
| Profit before tax | 1.76 | 2.44 | 2.35 | 4.02 |
| Tax % | 25.57% | 26.23% | 25.53% | 28.61% |
| Net profit | 1.31 | 1.79 | 1.75 | 2.87 |
| EPS (₹) | 5.24 | 1.43 | 1.02 | 1.67 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aptus Pharma Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 13.9 | 17.81 | 24.56 | 46.56 |
| Operating profit | 0.62 | 1.54 | 4.85 | 7.45 |
| OPM % | 4.46% | 8.65% | 19.75% | 16.00% |
| Net profit | 0.19 | 0.8 | 3.1 | 4.62 |
| EPS (₹) | 2.38 | 10.00 | 2.48 | 2.69 |
TTM is the trailing twelve months to the most recent quarter.
Aptus Pharma Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 0.30 | 0.30 | 5.00 | 6.86 |
| Reserves | 0.67 | 1.47 | 1.97 | 16.49 |
| Borrowings | 2.22 | 5.31 | 10.36 | 7.18 |
| Other liabilities | 3.02 | 2.95 | 4.59 | 13.01 |
| Total liabilities | 6.21 | 10.03 | 21.92 | 43.54 |
| Fixed assets | 0.52 | 0.63 | 0.99 | 2.77 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 5.69 | 9.40 | 20.93 | 40.77 |
| Total assets | 6.21 | 10.03 | 21.92 | 43.54 |
As reported by the company. Total assets equal total liabilities by construction.
Aptus Pharma Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | -0.18 | -2.17 | -1.84 | -5.60 |
| Cash from investing | -0.35 | -0.30 | -0.54 | -6.37 |
| Cash from financing | 0.81 | 2.86 | 6.68 | 7.79 |
| Net cash flow | 0.28 | 0.38 | 4.30 | -4.19 |
| Free cash flow | -0.53 | -2.50 | -2.46 | -7.79 |
| CFO / operating profit | -10% | -119% | -15% | -59% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Aptus Pharma Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | 26.48% | 38.18% | 29.96% |
| Debtor days | 63.02 | 68.66 | 83.82 | 147.07 |
| Inventory days | 176.00 | 183.57 | 285.06 | 231.78 |
| Days payable | 104.07 | 72.25 | 52.89 | 139.37 |
| Cash conversion cycle | 134.95 | 179.97 | 315.98 | 239.47 |
| Working capital days | 51.99 | 67.02 | 36.41 | 116.81 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Aptus Pharma Ltd shareholding pattern
Promoters held 72.89% at Jun 2026, broadly unchanged since Sep 2025. FIIs 0.00% and DIIs 0.00%.
| % held | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Promoters | 72.89% | 72.89% | 72.89% | 72.89% |
| FIIs | 10.03% | 0.00% | 0.00% | 0.00% |
| DIIs | 2.80% | 0.00% | 0.00% | 0.00% |
| Public | 14.29% | 27.11% | 27.11% | 27.11% |
| No. of shareholders | 213 | 302 | 337 | 686 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Aptus Pharma Ltd corporate filings
- Compliance Certificate uner Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- Closure of trading window under Insider Trading CodeInsider Trading / SASTlow impact
- Aptus Pharma Ltd schedules investor interaction for September 17, 2026Company Updatelow impact
Cruxal's analysis: Aptus Pharma Ltd has issued an intimation regarding an upcoming investor meeting or…
Read the full analysis - Aptus Pharma Limited secures shareholder approval for preferential allotment of equity shares at 16th AGMAGM/EGMhigh impact
Cruxal's analysis: Aptus Pharma Limited has successfully concluded its 16th Annual General Meeting, where…
Read the full analysis - Aptus Pharma Limited Announces 16th AGM Proceedings and Proposes Preferential Allotment of Equity SharesAGM/EGMmedium impact
Cruxal's analysis: Aptus Pharma Limited has concluded its 16th Annual General Meeting, where shareholders…
Read the full analysis - Aptus Pharma Ltd schedules investor interaction for September 12, 2026Company Updatelow impact
Cruxal's analysis: Aptus Pharma Ltd has issued an intimation regarding an upcoming investor meeting…
Read the full analysis - Aptus Pharma Ltd submits newspaper advertisement for financial resultsCompany Updatelow impact
Cruxal's analysis: Aptus Pharma Ltd has submitted a copy of the newspaper advertisement regarding the…
Read the full analysis - Aptus Pharma Limited Issues Corrigendum to AGM Notice Regarding Preferential Issue of 16.03 Lakh Equity SharesAGM/EGMlow impact
Cruxal's analysis: Aptus Pharma Limited has issued a corrigendum to its 16th Annual General Meeting notice…
Read the full analysis - Aptus Pharma announces strategic growth roadmap focusing on manufacturing and global market expansionCompany Updatelow impact
Cruxal's analysis: Aptus Pharma has released a strategic update outlining its next growth phase, which…
Read the full analysis - Aptus Pharma Limited Reports Strong FY26 Financials with 89.7% Revenue Growth and 49.0% PAT GrowthCompany Updatehigh impact
Cruxal's analysis: Aptus Pharma Limited has released its investor presentation for the financial year ended…
Read the full analysis - Aptus Pharma Limited Announces FY 2025-26 Annual Report and Proposes Preferential Issue of 16.03 Lakh Equity SharesOthershigh impact
Cruxal's analysis: Aptus Pharma Limited has released its FY 2025-26 Annual Report, highlighting strong…
Read the full analysis - Aptus Pharma Limited Announces Preferential Allotment of 16.03 lakh Equity Shares to Raise INR 44.88 CroreAGM/EGMhigh impact
Cruxal's analysis: Aptus Pharma Limited has announced a preferential allotment of 16,02,870 equity shares at…
Read the full analysis - Aptus Pharma Limited approves preferential issue of 16.03 lakh equity shares to raise INR 44.88 croreBoard Meetingmedium impact
Cruxal's analysis: Aptus Pharma Limited has announced the approval of a preferential issue of 16.03 lakh…
Read the full analysis - Aptus Pharma Limited Announces Board Meeting to Consider Preferential Issue of 16.10 lakh Equity SharesBoard Meetingmedium impact
Cruxal's analysis: Aptus Pharma Limited has scheduled a Board Meeting for August 17, 2026, to deliberate on…
Read the full analysis - Aptus Pharma Limited issues clarification regarding typographical errors in previous board meeting outcomeCompany Updatelow impact
Cruxal's analysis: Aptus Pharma Limited has issued a formal clarification to the BSE regarding minor…
Read the full analysis - Aptus Pharma Limited Announces Preferential Issue of 16.10 Lakh Equity Shares to 192 InvestorsBoard Meetingmedium impact
Cruxal's analysis: Aptus Pharma Limited has announced a board-approved preferential issue of 16,10,100…
Read the full analysis - Aptus Pharma Limited announces board meeting to consider fundraising via preferential allotmentBoard Meetingmedium impact
Cruxal's analysis: Aptus Pharma Limited has scheduled a board meeting for August 8, 2026, to evaluate a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.